On Jun. 21, 2021, Juventas Cell Therapy Ltd. and the Hematology Hospital of Chinese Academy of Medical Sciences (the Institute of Hematology of Chinese Academy of Medical Sciences) (hereinafter referred to as the “Institute”) entered into the Agreement on Strategic Cooperation in Cell Therapy New Drug Development in Tianjin. The two parties announced that they will work together and draw on each other’s strengths to explore technological innovation and new drug development based on CAR technology, iPSCs technology, etc. This means that the national scientific research and medical institute that pioneered cell therapy in China and the China-based new technology-driven bio-pharmaceutical company will join hands to explore the global market of immune cell therapies and biomedicine.
Juventas is a bio-pharmaceutical company driven by the new-generation cell and gene technology with headquarters located in China. Under three years after its establishment, two clinical trials of CNCT19 cell injection with independent intellectual property rights have entered the phase II, and the product was granted the Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation of China National Medical Products Administration. In particular, the product for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (r/r ALL) are expected to fill the gap in the global market.
The Institute is currently the largest national research-based medical organization for blood diseases in China, which integrates medical treatment, scientific research, talent cultivation, and the medical industry. It is understood that the immune cell therapy technology platforms based on the (Chimeric Antigen Receptor) CAR and the (induced Pluripotent Stem Cells) iPSCs are the most significant part of this specific agreement between the two parties.
This cooperation between Juventas and the leading national institute will firstly win more clinical resources for the cell therapy in China, because of its great potential and attractive landscape, secondly, it underlines the sustainable cycle of “technology transfer from the institute to the product in the market”, and finally, it significantly enhances the competitiveness of China’s cell therapy industry in the world. Experts believe that the in-depth cooperation between Juventas and the leading institute in China is one of the most efficient models of innovative drug research and development and industrialization driven by cell and gene technologies.
The strategic cooperation is also a milestone for both Juventas and the Institute to prepare for global competition. Dr. Lv Lulu, CEO of Juventas, said that the company will step up the efforts to improve the breadth and depth of industrial layout, project incubation, and scientific research by relying on its high-standard and highly efficient processes and technologies to gain international presence.